Mood stabilizers for patients with bipolar disorder: The state of the art

A. Carlo Altamura, Licia Lietti, Cristina Dobrea, Beatrice Benatti, Chiara Arici, Bernardo Dellosso

Research output: Contribution to journalArticle

Abstract

Bipolar disorder (BD) is a prevalent and disabling condition, often comorbid with other medical and psychiatric conditions and frequently misdiagnosed. International treatment guidelines for BD recommend the use of mood stabilizers - either in monotherapy or in association - as the gold standard in both acute and long-term therapy. Commonly used in the clinical practice of BD, mood stabilizers have represented an evolving field over the last few years. The concept of stabilization, in fact, has been stressed as the ultimate objective of the treatment of BD, given the chronic and recurrent nature of the illness, which accounts for its significant levels of impairment and disability. To date, different compounds are included within the broad class of mood stabilizers, with lithium, anticonvulsants and, more recently, atypical antipsychotics being the most representative agents. This article is aimed at providing an updated review of the available literature in relation to the role of mood stabilizers in BD, with particular emphasis on their mechanism of action, main clinical aspects and specific use in the different phases of BD treatment, according to the most recently published international treatment guidelines.

Original languageEnglish
Pages (from-to)85-99
Number of pages15
JournalExpert Review of Neurotherapeutics
Volume11
Issue number1
DOIs
Publication statusPublished - Jan 2011

Fingerprint

Bipolar Disorder
Guidelines
Therapeutics
Diagnostic Errors
Lithium
Anticonvulsants
Antipsychotic Agents
Psychiatry

Keywords

  • acute treatment
  • anticonvulsants
  • atypical antipsychotics
  • bipolar disorder
  • depression
  • lithium
  • maintenance treatment
  • mania
  • mood stabilizers

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)
  • Pharmacology (medical)

Cite this

Mood stabilizers for patients with bipolar disorder : The state of the art. / Altamura, A. Carlo; Lietti, Licia; Dobrea, Cristina; Benatti, Beatrice; Arici, Chiara; Dellosso, Bernardo.

In: Expert Review of Neurotherapeutics, Vol. 11, No. 1, 01.2011, p. 85-99.

Research output: Contribution to journalArticle

Altamura, A. Carlo ; Lietti, Licia ; Dobrea, Cristina ; Benatti, Beatrice ; Arici, Chiara ; Dellosso, Bernardo. / Mood stabilizers for patients with bipolar disorder : The state of the art. In: Expert Review of Neurotherapeutics. 2011 ; Vol. 11, No. 1. pp. 85-99.
@article{392d75059a4047048297da8fd2d73a6d,
title = "Mood stabilizers for patients with bipolar disorder: The state of the art",
abstract = "Bipolar disorder (BD) is a prevalent and disabling condition, often comorbid with other medical and psychiatric conditions and frequently misdiagnosed. International treatment guidelines for BD recommend the use of mood stabilizers - either in monotherapy or in association - as the gold standard in both acute and long-term therapy. Commonly used in the clinical practice of BD, mood stabilizers have represented an evolving field over the last few years. The concept of stabilization, in fact, has been stressed as the ultimate objective of the treatment of BD, given the chronic and recurrent nature of the illness, which accounts for its significant levels of impairment and disability. To date, different compounds are included within the broad class of mood stabilizers, with lithium, anticonvulsants and, more recently, atypical antipsychotics being the most representative agents. This article is aimed at providing an updated review of the available literature in relation to the role of mood stabilizers in BD, with particular emphasis on their mechanism of action, main clinical aspects and specific use in the different phases of BD treatment, according to the most recently published international treatment guidelines.",
keywords = "acute treatment, anticonvulsants, atypical antipsychotics, bipolar disorder, depression, lithium, maintenance treatment, mania, mood stabilizers",
author = "Altamura, {A. Carlo} and Licia Lietti and Cristina Dobrea and Beatrice Benatti and Chiara Arici and Bernardo Dellosso",
year = "2011",
month = "1",
doi = "10.1586/ern.10.181",
language = "English",
volume = "11",
pages = "85--99",
journal = "Expert Review of Neurotherapeutics",
issn = "1473-7175",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - Mood stabilizers for patients with bipolar disorder

T2 - The state of the art

AU - Altamura, A. Carlo

AU - Lietti, Licia

AU - Dobrea, Cristina

AU - Benatti, Beatrice

AU - Arici, Chiara

AU - Dellosso, Bernardo

PY - 2011/1

Y1 - 2011/1

N2 - Bipolar disorder (BD) is a prevalent and disabling condition, often comorbid with other medical and psychiatric conditions and frequently misdiagnosed. International treatment guidelines for BD recommend the use of mood stabilizers - either in monotherapy or in association - as the gold standard in both acute and long-term therapy. Commonly used in the clinical practice of BD, mood stabilizers have represented an evolving field over the last few years. The concept of stabilization, in fact, has been stressed as the ultimate objective of the treatment of BD, given the chronic and recurrent nature of the illness, which accounts for its significant levels of impairment and disability. To date, different compounds are included within the broad class of mood stabilizers, with lithium, anticonvulsants and, more recently, atypical antipsychotics being the most representative agents. This article is aimed at providing an updated review of the available literature in relation to the role of mood stabilizers in BD, with particular emphasis on their mechanism of action, main clinical aspects and specific use in the different phases of BD treatment, according to the most recently published international treatment guidelines.

AB - Bipolar disorder (BD) is a prevalent and disabling condition, often comorbid with other medical and psychiatric conditions and frequently misdiagnosed. International treatment guidelines for BD recommend the use of mood stabilizers - either in monotherapy or in association - as the gold standard in both acute and long-term therapy. Commonly used in the clinical practice of BD, mood stabilizers have represented an evolving field over the last few years. The concept of stabilization, in fact, has been stressed as the ultimate objective of the treatment of BD, given the chronic and recurrent nature of the illness, which accounts for its significant levels of impairment and disability. To date, different compounds are included within the broad class of mood stabilizers, with lithium, anticonvulsants and, more recently, atypical antipsychotics being the most representative agents. This article is aimed at providing an updated review of the available literature in relation to the role of mood stabilizers in BD, with particular emphasis on their mechanism of action, main clinical aspects and specific use in the different phases of BD treatment, according to the most recently published international treatment guidelines.

KW - acute treatment

KW - anticonvulsants

KW - atypical antipsychotics

KW - bipolar disorder

KW - depression

KW - lithium

KW - maintenance treatment

KW - mania

KW - mood stabilizers

UR - http://www.scopus.com/inward/record.url?scp=78650405997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650405997&partnerID=8YFLogxK

U2 - 10.1586/ern.10.181

DO - 10.1586/ern.10.181

M3 - Article

C2 - 21158558

AN - SCOPUS:78650405997

VL - 11

SP - 85

EP - 99

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

SN - 1473-7175

IS - 1

ER -